Centre for Ocular Research & Education
Waterloo, Ontario, N2L 3G1, Canada
NCT Number: NCT04201639
The purpose of this study is to evaluate the performance of Precision1 DD CLs with regard to subjective symptoms (dryness, comfort, vision), lens fit and time to haze in CL wearers who identify themselves as heavy digital devices users (at least 6 hours of digital device use per day).
Looking for future studies?
Notify Me18 year–40 year
All sexes
Interventional
Not applicable
Waterloo, Ontario, N2L 3G1, Canada
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
Other names: Precision1™
Time frame: Dispense Visit (Day 0)
Participants rate their comfort after insertion on a scale from 0 (worst) to 100 (best).
Time frame: Dispense Visit (Day 0)
Participants rate their dryness after insertion on a scale from 0 (worst) to 100 (best).
Time frame: Dispense Visit (Day 0)
Participants rate their clarity of vision after insertion on a scale from 0 (worst) to 100 (best).
Time frame: Day 1
Participants rate their comfort after insertion on a scale from 0 (worst) to 100 (best).
Time frame: Day 1
Participants rate their dryness after insertion on a scale from 0 (worst) to 100 (best).
Time frame: Day 1
Participants rate their clarity of vision after insertion on a scale from 0 (worst) to 100 (best).
Time frame: Day 7
Participants rate their comfort after insertion on a scale from 0 (worst) to 100 (best).
Time frame: Day 7
Participants rate their dryness after insertion on a scale from 0 (worst) to 100 (best).
Time frame: Day 7
Participants rate their clarity of vision after insertion on a scale from 0 (worst) to 100 (best).
Time frame: Day 10
Participants rate their comfort after insertion on a scale from 0 (worst) to 100 (best).
Time frame: Day 10
Participants rate their dryness after insertion on a scale from 0 (worst) to 100 (best).
Time frame: Day 10
Participants rate their clarity of vision after insertion on a scale from 0 (worst) to 100 (best).
Time frame: Followup visit (occurring at a single visit any day from Day 12-16)
Participants rate their comfort after insertion on a scale from 0 (worst) to 100 (best).
Time frame: Followup visit (occurring at a single visit any day from Day 12-16)
Participants rate their comfort after insertion on a scale from 0 (worst) to 100 (best).
Time frame: Followup visit (occurring at a single visit any day from Day 12-16)
Participants rate their comfort after insertion on a scale from 0 (worst) to 100 (best).
Time frame: Day 1
Participants rate their comfort after 6 hours of digital device use on a scale from 0 (worst) to 100 (best).
Time frame: Day 1
Participants rate their dryness after 6 hours of digital device use on a scale from 0 (worst) to 100 (best).
Time frame: Day 1
Participants rate their vision clarity after 6 hours of digital device use on a scale from 0 (worst) to 100 (best).
Time frame: Day 7
Participants rate their comfort after 6 hours of digital device use on a scale from 0 (worst) to 100 (best).
Time frame: Day 7
Participants rate their dryness after 6 hours of digital device use on a scale from 0 (worst) to 100 (best).
Time frame: Day 7
Participants rate their vision clarity after 6 hours of digital device use on a scale from 0 (worst) to 100 (best).
Time frame: Day 10
Participants rate their comfort after 6 hours of digital device use on a scale from 0 (worst) to 100 (best).
Time frame: Day 10
Participants rate their dryness after 6 hours of digital device use on a scale from 0 (worst) to 100 (best).
Time frame: Day 10
Participants rate their vision clarity after 6 hours of digital device use on a scale from 0 (worst) to 100 (best).
Time frame: Followup visit (occurring at a single visit any day from Day 12-16)
Participants rate their comfort after 6 hours of digital device use on a scale from 0 (worst) to 100 (best).
Time frame: Followup visit (occurring at a single visit any day from Day 12-16)
Participants rate their dryness after 6 hours of digital device use on a scale from 0 (worst) to 100 (best).
Time frame: Followup visit (occurring at a single visit any day from Day 12-16)
Participants rate their vision clarity after 6 hours of digital device use on a scale from 0 (worst) to 100 (best).
Time frame: Day 1
Participants rate their end of day comfort on a scale from 0 (worst) to 100 (best).
Time frame: Day 1
Participants rate their end of day dryness on a scale from 0 (worst) to 100 (best).
Time frame: Day 1
Participants rate their end of day vision clarity on a scale from 0 (worst) to 100 (best).
Time frame: Day 7
Participants rate their end of day comfort on a scale from 0 (worst) to 100 (best).
Time frame: Day 7
Participants rate their end of day dryness on a scale from 0 (worst) to 100 (best).
Time frame: Day 7
Participants rate their end of day rating of vision clarity on a scale from 0 (worst) to 100 (best).
Time frame: Day 10
Participants rate their end of day comfort on a scale from 0 (worst) to 100 (best).
Time frame: Day 10
Participants rate their end of day dryness on a scale from 0 (worst) to 100 (best).
Time frame: Day 10
Participants rate their end of day vision clarity on a scale from 0 (worst) to 100 (best).
Time frame: Followup visit (occurring at a single visit any day from Day 12-16)
Participants rate their end of day comfort on a scale from 0 (worst) to 100 (best).
Time frame: Followup visit (occurring at a single visit any day from Day 12-16)
Participants rate their end of day dryness on a scale from 0 (worst) to 100 (best).
Time frame: Followup visit (occurring at a single visit any day from Day 12-16)
Participants rate their end of day rating of vision clarity on a scale from 0 (worst) to 100 (best).
University of Waterloo
Other
Acronym: PUG
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03334253
Eye Diseases, Myopia
Birmingham, Alabama, United States
View Trial DetailsNCT07087665
Eye Diseases, Myopia
Saint Louis Park, Minnesota, United States
View Trial DetailsNCT06700460
Eye Diseases, Myopia
Omaha, Nebraska, United States
View Trial DetailsNCT00320593
Eye Diseases, Myopia
Birmingham, Alabama, United States
View Trial Details